Amanote Research
Register
Sign In
Anti-Interleukin 6 Receptor Antibody Treatment in Rheumatic Disease
Annals of the Rheumatic Diseases
- United Kingdom
doi 10.1136/ard.59.suppl_1.i21
Full Text
Open PDF
Abstract
Available in
full text
Categories
Immunology
Molecular Biology
Biochemistry
Rheumatology
Allergy
Genetics
Date
November 1, 2000
Authors
N. Nishimoto
Publisher
BMJ
Related search
Tocilizumab, a Humanized Anti-Interleukin-6 Receptor Antibody, for Treatment of Rheumatoid Arthritis
Open Access Rheumatology: Research and Reviews
Rheumatology
Anti-Interleukin-6 Receptor Antibody Therapy —From Bedside to Bench—
Japanese Journal of Clinical Immunology
Efficacy of Epidural Administration of Anti-Interleukin-6 Receptor Antibody Onto Spinal Nerve for Treatment of Sciatica
Global Spine Journal
Orthopedics
Surgery
Neurology
Sports Medicine
Anti-Interleukin-6 Receptor Antibody Reduces Neuropathic Pain Following Spinal Cord Injury in Mice
Experimental and Therapeutic Medicine
Medicine
Cancer Research
Immunology
Microbiology
Association of Interleukin 6 Receptor Variant With Cardiovascular Disease Effects of Interleukin 6 Receptor Blocking Therapy
JAMA Cardiology
Cardiovascular Medicine
Cardiology
Anti-Il-6 Receptor Antibody Causes Less Promotion of Tuberculosis Infection Than Anti-TNF- Antibody in Mice
Clinical and Developmental Immunology
Orphan Designation: Humanised Anti-Il-6 Receptor Monoclonal Antibody, Treatment of Neuromyelitis Optica Spectrum Disorders
Case Medical Research
Antitumor Efficacy of the Anti-Interleukin-6 (IL-6) Antibody Siltuximab in Mouse Xenograft Models of Lung Cancer
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Exacerbation of Chronic Active Epstein-Barr Virus Infection in a Patient With Rheumatoid Arthritis Receiving Humanised Anti-Interleukin-6 Receptor Monoclonal Antibody
Annals of the Rheumatic Diseases
Immunology
Molecular Biology
Biochemistry
Rheumatology
Allergy
Genetics
